DOCUMENTS

papers

Effect of specialized diagnostic assessment units on the time to diagnosis in screen-detected breast cancer patients

Published: May 5, 2015
Category: Papers
Authors: Gilbert J, Groome PA, Jiang L, Langley H, Moineddin R
Country: Canada
Language: null
Type: Performance Analysis
Settings: Hospital, PCP

Br J Cancer 112:1744-1750.

Queen’s University, 10 Stuart Street, Kingston, ON, Canada; Cancer Care Ontario, Toronto, ON, Canada; Kingston General Hospital, Kingston, ON, Canada; University of Toronto, Toronto, ON, Canada

BACKGROUND: The duration of the cancer diagnostic process has considerable influence on patients’ psychosocial well-being. Breast diagnostic assessment units (DAUs) in Ontario, Canada are designed to improve the quality and timeliness of care during a breast cancer diagnosis. We compared the diagnostic duration of patients diagnosed through a DAU vs usual care (UC).

METHODS: Retrospective population-based cohort study of 2499 screen-detected breast cancers (2011) using administrative health-care databases linked to the Ontario Cancer Registry. The diagnostic interval was measured from the initial screen to cancer diagnosis. Diagnostic assessment unit use was based on the biopsy and/or surgery hospital. We compared the length of the diagnostic interval between the DAU groups using multivariable quantile regression.

RESULTS: Diagnostic assessment units had a higher proportion of patients
diagnosed within the 7-week target compared with UC (79.1% vs 70.2%, P0.001). The median time to diagnosis at DAUs was 26 days, which was 9 days shorter compared with UC (95% CI: 6.4-11.6). This effect ws reduced to 8.3 days after adjusting for all study covariates. Adjusted DAU differences were similar at the 75th and 90th percentiles of the diagnostic interval distribution.

CONCLUSIONS: Diagnosis through an Ontario DAU was associated with a reduced time to diagnosis for screen-detected breast cancer patients, which likely reduces the anxiety and distress associated with waiting for a diagnosis.

PMID: 25942395
PMCID: PMC4647239

High-Impact Chronic Conditions,Duration,Severity,Canada,Morbidity Pattern,Aged,Breast Neoplasms/pathology,Female,Mass Screening,Middle Aged

Please log in/register to access.

Log in/Register

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System.
All rights reserved. Terms of Use Privacy Statement

Back to top